East Sussex - Better Together
NHS

2.12 Lipid-regulating drugs

NICE CG71: Familial hypercholesterolaemia: identification and management

NICE CG172: Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease

NICE CG181: Cardiovascular disease: risk assessment and reduction, including lipid modification

 

Reduction in Low density lipoprotein cholesterol

Dose (mg/day)

5

10

20

40

80

Fluvastatin

-

-

21%1

27%1

33%2

Pravastatin

-

20%1

24%1

29%1

-

Simvastatin

-

27%1

32%2

37%2

42%3,4

Atorvastatin

-

37%2

43%3

49%3

55%3

Rosuvastatin

38%2

43%3

48%3

53%3

-

1 20% - 30%: low intensity

2 31% - 40%: medium intensity

3 above 40%: high intensity

4 Advice from the MHRA: there is an increased risk of myopathy associated with high-dose (80 mg) simvastatin. The 80 mg dose should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks.

 

  • First Line Drugs
  • Second Line Drugs
  • Specialist Initiated Drugs
  • Specialist Only Drugs
  • Mixed Status